Another strategy, developed later by Yu et al (63), recognized that anti-CD37 monoclonal antibody immunoliposomes could be used as carriers for specific targeting of B-CLL cells. This evidence concerns the gene CD37 and B-cell chronic lymphocytic leukemia.